Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY) Zepbound from flooding the market.

The group led by U.S. Representative Richard Hudson and Herbert Conaway wrote the letter urging immediate action against the rising threat of illegal, counterfeit anti-obesity medications entering the U.S. 

The letter stated that these counterfeit products, including unapproved versions of the active ingredients in Ozempic and Wegovy, which are often smuggled from unregistered foreign suppliers, primarily in China, pose a serious risk ...